Advertisement
Document › Details
Evolva Holding S.A.. (7/6/17). "Press Release: Neil Goldsmith Stepping Down as CEO and Board Member of Evolva".
Organisation | Evolva Holding SA (SIX: EVE) | |
Group | Lallemand (Group) | |
Organisation 2 | Abunda Nutrition Inc. | |
Today | Evolva Nutrition Inc. | |
Group | Lallemand (Group) | |
Product | food ingredient | |
Product 2 | nootkatone | |
Person | Goldsmith, Neil (Sundew 202009 Chairman before Evolva –200910–201707 CEO STEPPED DOWN 7/17) | |
Person 2 | Waddington, Simon (Evolva 201707–201807 CEO before COO before Abunda Nutrition CEO RESIGNED 7/18) | |
Evolva (SIX: EVE) today announces the departure of CEO Neil Goldsmith and his succession by the current Chief Operating Officer (COO), Simon Waddington.
Since co-founding Evolva, Neil Goldsmith has been instrumental in Evolva’s development over the last thirteen years, moving the company from a pharmaceutical oriented biotech start-up to a listed business developing and selling specialty ingredients for health, wellness and nutrition markets. Neil’s entrepreneurial approach has led to the launch by Evolva of products such as nootkatone and resveratrol, and the advancement of best-tasting stevia products to an anticipated launch in 2018, as communicated earlier this year.
Evolva’s Board and executive management have recently determined that the near-term focus needs to be on growing the market opportunity for Evolva’s products and delivering attractive margins. This more focused approach is not a natural fit with Neil’s entrepreneurial strengths, something recognised by both Neil and the Board. As a consequence Neil and the Board have mutually agreed that Neil will step down as CEO and member of the Evolva Board with immediate effect.
Neil will be succeeded by Simon Waddington, currently COO of Evolva. Simon had previously been the CEO of Abunda Inc. until its acquisition by Evolva in 2011 upon which he joined the management team. His background and experience is ideally suited to the next phase of Evolva’s evolution.
Gerard Hoetmer, Chairman of Evolva’s Board of Directors, said “On behalf of the whole Board, I would like to thank Neil for all his efforts to bring Evolva to where it is today. We are confident that under Simon’s leadership the next steps in the transformation of Evolva to a product-based business can be made. More information on the transformation will be shared at the half-year results announcement on August 14th.”
– ends –
About Evolva
Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information see www.evolva.com. Questions about our approach? Have a look at our video.
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
Contact Details
Oliver Walker
oliverw@evolva.com
+ 41 61 485 2034
Paul Verbraeken
paulv@evolva.com
+ 41 61 485 2035
Stephan Herrera
stephanh@evolva.com
+ 1 415 794 4005
Record changed: 2023-06-05 |
Advertisement
More documents for Lallemand (Group)
- [1] Evolva Holding S.A.. (11/21/23). "Press Release: Evolva Enters into an Agreement to Sell Its Operations to Lallemand, Securing the Best Possible Outcome for the Company and Its Stakeholders". Reinach....
- [2] Evolva Holding S.A.. (11/14/23). "Press Release: Evolva and Breko Broaden Partnership by Signing Agreement for the Exclusive Distribution of Veri-te Resveratrol in Germany, Austria, Thailand and Vietnam". Reinach....
- [3] Evolva Holding S.A.. (8/23/22). "Press Release: Evolva Statement to SER Communication. Evolva Takes Note of the Sanction Request Submitted by SIX Exchange Regulation (SER) Today". Reinach....
- [4] Evolva Holding S.A.. (2/28/22). "Press Release: Carsten Däweritz Remains CFO of Evolva". Reinach....
- [5] Evolva Holding S.A.. (2/8/22). "Press Release: Evolva Appoints Christian Wichert as New CEO to Boost Growth Strategy and Enter Its Next Phase of Development and Commercialization". Reinach....
- [6] Evolva Holding S.A.. (12/27/21). "Press Release: Evolva Secures Additional Financing Lines to Accelerate Its Growth". Reinach....
- [7] Evolva Holding S.A.. (11/30/21). "Press Release: Evolva Announces Private Placement of 63.8m Shares to Veraison Raising Gross Proceeds of CHF 7.5m and CFO Departure". Reinach....
- [8] Evolva S.A.. (3/24/21). "Press Release: Evolva Announces New Chief Financial Officer". Reinach....
- [9] Evolva Holding S.A.. (7/10/18). "Press Release: Evolva Announces Oliver Walker to Succeed Simon Waddington as CEO"....
- [10] Evolva Holding S.A.. (10/26/17). "Press Release: Evolva Announces Final Terms of Proposed Capital Increase [Not for release in US, CA, JP or AU or any jurisdiction where unlawful]"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top